Dorsey Wright & Associates boosted its position in Genmab A/S Sponsored ADR (NASDAQ:GMAB – Free Report) by 43.6% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 64,388 shares of the company’s stock after purchasing an additional 19,551 shares during the quarter. Dorsey Wright & Associates’ holdings in Genmab A/S were worth $1,728,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. CIBC Private Wealth Group LLC boosted its position in Genmab A/S by 291.9% during the fourth quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock worth $25,000 after acquiring an additional 616 shares during the last quarter. Osaic Holdings Inc. raised its holdings in Genmab A/S by 37.8% in the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after acquiring an additional 440 shares during the last quarter. V Square Quantitative Management LLC acquired a new position in Genmab A/S in the 1st quarter valued at $34,000. NewEdge Advisors LLC lifted its stake in shares of Genmab A/S by 1,229.0% during the 3rd quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock worth $38,000 after purchasing an additional 1,143 shares during the period. Finally, Brown Brothers Harriman & Co. lifted its stake in shares of Genmab A/S by 143.4% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock worth $41,000 after purchasing an additional 780 shares during the period. 7.07% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of equities research analysts have recently commented on GMAB shares. The Goldman Sachs Group raised Genmab A/S from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 22nd. HC Wainwright increased their target price on Genmab A/S from $38.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, July 2nd. BNP Paribas Exane raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, April 22nd. Weiss Ratings cut Genmab A/S from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, May 8th. Finally, Truist Financial began coverage on Genmab A/S in a report on Wednesday, May 27th. They issued a “buy” rating and a $40.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.21.
Genmab A/S Stock Performance
Shares of GMAB stock opened at $28.72 on Friday. The company’s fifty day simple moving average is $26.62 and its 200-day simple moving average is $28.42. Genmab A/S Sponsored ADR has a 52 week low of $21.00 and a 52 week high of $35.43. The company has a current ratio of 2.18, a quick ratio of 2.17 and a debt-to-equity ratio of 0.87. The company has a market cap of $17.91 billion, a PE ratio of 21.76, a P/E/G ratio of 1.84 and a beta of 0.84.
Genmab A/S Company Profile
Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.
Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.
Featured Stories
- Five stocks we like better than Genmab A/S
- AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector
- Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth
- TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident
- GE Aerospace Faces a Prove-It Moment in Q2 Earnings
Want to see what other hedge funds are holding GMAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genmab A/S Sponsored ADR (NASDAQ:GMAB – Free Report).
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
